Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation

por Thiel, V N, Giaimo, B D, Schwarz, P, Soller, K, Vas, V, Bartkuhn, M, Blätte, T J, Döhner, K, Bullinger, L, Borggrefe, T, Geiger, H, Oswald, F
Publicado 2017

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial

por Hammersen, J., Birndt, S., Döhner, K., Reuken, P., Stallmach, A., Sauerbrey, P., La Rosée, F., Pfirrmann, M., Fabisch, C., Weiss, M., Träger, K., Bremer, H., Russo, S., Illerhaus, G., Drömann, D., Schneider, S., La Rosée, P., Hochhaus, A.
Publicado 2023

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia

por Schlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U., Wessendorf, S., Runde, V., Tischler, H. J., Bentz, M., Koller, E., Heuser, M., Thol, F., Benner, A., Ganser, A., Döhner, K., Döhner, H.
Publicado 2023

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA

por Stegelmann, F., Jahn, E., Koschmieder, S., Heidel, F., Hochhaus, A., Hebart, H., Isfort, S., Reiter, A., Bangerter, M., Waller, C. F., Wolleschak, D., Scheid, C., Göthert, J., Schafhausen, P., Kindler, T., Radsak, M. P., Gattermann, N., Möhle, R., von Bubnoff, N., Schrade, A., Brümmendorf, T., Döhner, H., Griesshammer, M., Döhner, K.
Publicado 2022

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia

por Krowiorz, K, Ruschmann, J, Lai, C, Ngom, M, Maetzig, T, Martins, V, Scheffold, A, Schneider, E, Pochert, N, Miller, C, Palmqvist, L, Staffas, A, Mulaw, M, Bohl, S R, Buske, C, Heuser, M, Kraus, J, O'Neill, K, Hansen, C L, Petriv, O I, Kestler, H, Döhner, H, Bullinger, L, Döhner, K, Humphries, R K, Rouhi, A, Kuchenbauer, F
Publicado 2016

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

por Schlenk, R F, Frech, P, Weber, D, Brossart, P, Horst, H-A, Kraemer, D, Held, G, Ringhoffer, M, Burchardt, A, Kobbe, G, Götze, K, Nachbaur, D, Fischer, T, Lübbert, M, Salih, H R, Salwender, H, Wulf, G, Koller, E, Wattad, M, Fiedler, W, Kremers, S, Kirchen, H, Hertenstein, B, Paschka, P, Gaidzik, V I, Teleanu, V, Heuser, M, Thol, F, Döhner, K, Krauter, J, Ganser, A, Döhner, H
Publicado 2017

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

por Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, Salih, H R, Held, G, Köhne, C-H, Götze, K, Lübbert, M, Kündgen, A, Brossart, P, Wattad, M, Salwender, H, Hertenstein, B, Nachbaur, D, Wulf, G, Horst, H-A, Kirchen, H, Fiedler, W, Raghavachar, A, Russ, G, Kremers, S, Koller, E, Runde, V, Heil, G, Weber, D, Göhring, G, Döhner, K, Ganser, A, Döhner, H, Schlenk, R F
Publicado 2017

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

por Schlenk, R. F., Weber, D., Herr, W., Wulf, G., Salih, H. R., Derigs, H. G., Kuendgen, A., Ringhoffer, M., Hertenstein, B., Martens, U. M., Grießhammer, M., Bernhard, H., Krauter, J., Girschikofsky, M., Wolf, D., Lange, E., Westermann, J., Koller, E., Kremers, S., Wattad, M., Heuser, M., Thol, F., Göhring, G., Haase, D., Teleanu, V., Gaidzik, V., Benner, A., Döhner, K., Ganser, A., Paschka, P., Döhner, H.
Publicado 2019

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

por Nagel, Gabriele, Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H. A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V. I., Paschka, P., Döhner, K., Ganser, A., Döhner, Hartmut, Schlenk, R. F.
Publicado 2017

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

por Hernández-Sánchez, A., Villaverde-Ramiro, Á., Martínez Elicegui, J., González, T., Benner, A., Sträng, E., Castellani, G., Heckman, C. A., Versluis, J., Abáigar, M., Sobas, M., Azibeiro, R., Tur, L., Valk, P. J., Metzeler, K. H., Ayala, R., Dall’Olio, D., Tettero, J., Martínez-López, J., Dombret, H., Pratcorona, M., Damm, F., Mills, K. I., Mayer, J., Thiede, C., Voso, M. T., Sanz, G. F., Calado, F., Döhner, K., Gaidzik, V. I., Heuser, M., Haferlach, T., Turki, A. T., Reinhardt, D., Villoria Medina, R., van Speybroeck, M., Schulze-Rath, R., Barbus, M., Butler, J. E., Hernández Rivas, J. M., Huntly, B. J., Ossenkoppele, G. J., Döhner, H., Bullinger, L.
Publicado 2022